<DOC>
	<DOCNO>NCT00017524</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness AG2037 treat patient advance , metastatic , recurrent solid tumor .</brief_summary>
	<brief_title>AG2037 Treating Patients With Advanced , Metastatic , Recurrent Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose-limiting toxic effect AG2037 patient advance , metastatic , recurrent solid tumor . - Determine safety tolerance drug patient . - Assess pharmacokinetics drug patient . - Document antitumor effect drug patient . OUTLINE : This dose-escalation , multicenter study . Patients receive AG2037 IV weekly week 1-3 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos AG2037 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . Patients follow weekly 4 week . PROJECTED ACCRUAL : A total 18-60 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor Advanced , metastatic , recurrent disease No curative therapy exist Measurable evaluable disease PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : At least 3 month Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 mg/dL ( unless due Gilbert 's syndrome ) SGOT OR SGPT great 2 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min Other : No unstable severe concurrent medical condition would preclude study participation No sociological familial condition would preclude study compliance No psychological addictive disorder would preclude study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosourea mitomycin ) recover Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy recover No prior radiotherapy 40 % bone marrow Surgery : Not specify Other : At least 2 week since prior blood transfusion At least 4 week since prior investigational agent recover No prior glycinamide ribonucleotide formyltransferase ( GARFT ) inhibitor No concurrent extradietary folate supplement No concurrent allopurinol No concurrent anticancer investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>